04/08/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/8/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the BD SARS-CoV-2 Reagents for BD MAX™ System, which received an Emergency Use Authorization from the Food and Drug Administration on April 8, 2020. The BD SARS-CoV-2 Reagents for BD MAX™ System is authorized for use on using respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
No hay comentarios:
Publicar un comentario